Synthetic versions of 'game-changing' new antibiotic created

Image
Press Trust of India London
Last Updated : May 02 2016 | 4:29 PM IST
Scientists, including one of Indian-origin, have successfully produced two synthetic derivatives of "game-changing" Teixobactin - the world's first known antibiotic capable of destroying drug resistant bacteria.
Teixobactin, which kills a range of pathogens without detectable resistance, was isolated from microorganisms found in soil - the natural source of nearly all antibiotics developed since the 1940s, researchers said.
Last year, the discovery of the antibiotic Teixobactin by researchers in the US was hailed as a 'game-changer' in the fight against antimicrobial resistance, they said.
In order for it to be developed as a potential drug treatment, several versions of the antibiotic must be produced via chemical synthesis in order to overcome the hurdles of drug development.
Now, researchers from University of Lincoln in the UK have become the first group of scientists to synthetically produce two derivatives of Teixobactin.
"Teixobactin originally evolved in soil to kill the bacteria around it, so our challenge was to produce the antibiotic synthetically," said Ishwar Singh from University of Lincoln.
"The method we created to do this uses commercially available 'building blocks' and has a single purification step," said Singh.
"We are now able to present the total synthesis of two derivatives of Teixobactin," he said.
"We have also been able to identify some of the properties of the antibiotic which are critical for its antimicrobial activities," he said.
"This is a very important stepping stone towards an in-depth study of Teixobactin and the quest for synthesising similar molecules which could prove vital in our fight against drug resistant bacteria," added Singh.
The bacteria against which Teixobactin is effective have, thus far, not shown any detectable resistance and given its mechanisms of attack, scientists are also confident that this is unlikely to occur in the future.
"The process of bringing an antibiotic to clinic is an extremely lengthy one and can often take around 10-15 years," said Singh.
The findings were published in the Royal Society of Chemistry journal.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: May 02 2016 | 4:29 PM IST

Next Story